In the 1980s, the Rijswijk TNO group including Ton Hagenbeek and Dirk van Bekkum developed the term minimal residual disease (MRD) on the basis of nifty experiments in a rat model of AML. In 1983 -1990 , Ton and Bob Lowenberg organized a series of symposia on MRD in leukemia. (I recall one planned evening cruise in Rotterdam harbor when we had a brilliant time eating, drinking and debating MRD but no one was certain whether the ship actually left the pier.) Alas, it seems the Dutch were way ahead of their time. Early enthusiasm for MRD testing was followed by a black hole similar to when a massive star collapses in on itself. However, massive star collapses also create supernovas: suddenly MRD testing has gone viral. A PUBMED Boolean search of publications in 2000-2014 using the search terms 'MRD' AND 'leukemia' OR 'lymphoma' identified about 96 000 citations, with 35 000 of those being published since 2010. This growth rate exceeds that of iPhones and Kindles. There are even Twitter and Facebook MRD blogs and chat rooms and even MRD groupies. What's going on? Will Google, Microsoft and Uber soon get into the MRD game? Is MRD a growth area for investors? But, more importantly, is this excitement warranted?
First, a word on nomenclature. Recently, the late John Goldman and I discussed why MRD is a jargon term and suggested that if we want to retain it as MRD, we should change 'minimal' to 'measureable'. The essence of our argument was 'minimal' compared to what? (see Figure 1) . To answer this question we need to know what is being sampled (blood, BM, something else), how representative is the sample of the disease in the individual being sampled, how sensitive and specific is the MRD detection assay (ideally from a receiver operating curve (ROC)), is the readout validated as a predictor of the clinical outcome of interest (such as relapse, disease-free survival or survival) and other complex issues. For example, the computer modeling that I did with John Klein and Anna Butturini several years ago showed that at low frequencies of leukemia cells in the body (say o10E+3) sample size, and not assay sensitivity, determines the test result. Simply put, if there are many leukemia cells in an individual there is likely to be one or more in a 5-10-mL blood or BM sample. However, if there are few leukemia cells in an individual there is no guarantee one will be in a small sample. It follows that if the sample does not contain at least one leukemia cell the test result will be negative even for the perfect MRD assay. So a negative test means no leukemia cells in the sample, but not no leukemia cells in the individual being tested.
Let us move to MRD testing in the context of blood cell transplants and BMTs, and start with whether it is better to be MRD negative or positive? Not a difficult question to answer, somewhat like asking whether is it better to be beautiful or ugly? This is essentially where we are with MRD testing. For example, is it surprising that individuals with AML, who are MRD positive by multiparameter flow cytometry after induction and consolidation therapy, have a greater likelihood of relapse than individuals who are MRD negative. Obviously not. Also, is it unexpected that some individuals who are MRD negative relapse? No, for reasons that I have discussed including inadequate sampling and imperfect test sensitivity. But what seems to be considerably more interesting to me is that a substantial proportion of individuals who are MRD positive (30-50% depending on other risk-factors) do not relapse (at least within a reasonable interval).
Is this surprising? No. First there is the issue of test specificity. False positives are to be expected with current MRD assays. This is driven by the lack of leukemia-specific genotypes and phenotypes. Although some may disagree, recall BCR/ABL1 transcripts are detected in normal individuals and that healthy individuals and individuals cured of low-grade lymphoma frequently have cells with t(14;18) or with the IGVH rearrangement specific to the neoplastic clone. The message is that detecting a mutation is not the same as detecting a neoplasm. For example, an oncogenic mutation might only cause cancer if it occurs in the 'right' (or from our perspective 'wrong') cell in the right microenvironment and there are other mechanisms of control of neoplasms such as the immune system.
My greatest concern about the use (or rather misuse) of results of MRD testing is in the context of therapy decisions. A few examples are: in several studies subjects with AML receive no further therapy, whereas subjects who are MRD positive are assigned (not randomized) to receive an investigational intervention such as a blood cell or BM allotransplant. This strategy potentially incorporates several fallacies including: (1) everyone who is MRD positive will relapse (clearly wrong); (2) intervening before relapse will result in a better outcome than intervening for MRD positivity (unproved); and (3) the new intervention will work in individuals failing conventional therapy (uncertain and probably wrong or at least naive). What we need are randomized trials in which MRD-positive subjects are randomly assigned to placebo or conventional therapy) vs the investigational intervention. We need to prove rather than believe that altering therapy based on MRD testing data is effective. (The same could be done for individuals who are MRD negative.) Does any of this make sense? If we consider multistep development of leukemias and lymphomas, the extensive clonal heterogeneity at diagnosis and the recent whole-genome sequencing studies exploring how and why people with leukemia relapse, it would be extraordinarily unlikely that the genotype and/or phenotype of leukemia or lymphoma would be static or resemble those at diagnosis. Accordingly, it seems unlikely that MRD testing will be a foolproof method of predicting relapse. Furthermore, many or most leukemia relapses occur from a leukemia stem or initiating cell whose genotype and phenotype are unknown to us and therefore, not the target of current MRD testing. The same concept also likely applies to lymphomas.
Another concern about MRD testing is its applicability. Even in a well-conducted prospective study in individuals with AML from the HOVON/SAKK group led by Gert Ossenkoppele, results of MRD testing informed treatment decisions in only about 20% of subjects who were entered into the study. (Does it seem that the Dutch are obsessed with MRD akin to wooden shoes, gouda and rijstaffel?) In less structured settings and without standardized MRD testing, applicability of MRD test results will likely be properly applied to even a smaller proportion of subjects. This could improve if additional targets for MRD testing become available and tests are highly sensitive and specific.
A final comment on a different type of transplant-related MRD testing: positron emission tomography (PET)-computer tomography (CT) scans (see Figure 2) . Some centers use PET-CTs to stage potential lymphoma transplant recipients. Others exclude individuals based on a positive PET-CT or alter pre-and/or post-transplant therapy or both based on results of PET-CT testing. Although data from PET-CTs are useful in assigning prognosis in the context of conventional lymphoma therapy, there are no convincing proofs of efficacy in the transplant setting. Nor are there convincing data that altering transplant therapy based on results of pre-or post-transplant PET-CT testing improves outcomes. These hypotheses need testing in randomized trials. And there are other issues with PET-CT testing to be worked out such as up-and downstaging with proper controls (the Will Rodgers effect) and standardization. Should we use a binary end point for PET-CT test results (negative/positive), the Deauville scale (spell-checker interestingly (or prophetically) tried to insert 'vaudeville'), change in sum of uptake values or something else? One should also recall that the radiation dose from a PET-CT is about 30 mSv; do six and you have given your patient the dose received by the average A-bomb survivor. I am certain that the data from PET-CT testing will be useful in the future; however, we need to determine how and when and not simply jump on the PET-CT testing bandwagon.
I realize that my views on the value of MRD testing are not what many people wish to believe and others will judge my conclusions to be wrong. My door is always open to contrary views. (I was told to say this.) Please correct me on: Twitter: RPG#MRD.
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